ERS International Congress, Dietary Flavonoids for COPD and More

[ad_1]

October 04, 2022

2 minute read


We have not been able to process your request. Please try again later. If you continue to have this problem, please contact [email protected]

Healio editors have compiled the most read respiratory news published in September.

Highlights include a study that found dietary flavonoids can blunt smoking-related COPD risk; highlights from the International Congress of the European Respiratory Society, including the effects of vilobelimab on mortality in patients with severe COVID-19 pneumonia and sustained quality of life at 2 years after treatment with a valve system aspiration for emphysema; new research that has shown that exposure to second-hand airline smoke worsens respiratory health; and more.





Source: Adobe Stock

Read these articles, and more, below, in no particular order.

Dietary Flavonoids May Mitigate Some Risks of Smoking-Related COPD

According to a study published in European Respiratory Journal. Read more

Vilobelimab may reduce mortality in patients with severe COVID-19 pneumonia

Vilobelimab treatment reduced mortality by 28 to 60 days in patients with severe COVID-19 pneumonia without increasing infections, according to data presented at the ERS International Congress. Read more

Icienticaftor shows promise for patients with COPD and chronic bronchitis

Icenticaftor did not show a dose response for FEV1 at 12 weeks, but the treatment was associated with improved symptoms at 24 weeks in patients with COPD and chronic bronchitis on triple inhaled therapy, reported researchers at the ERS International Congress. Lily more

Breathing Valve System for Emphysema Provides Sustained Quality of Life Benefit at 2 Years

Patients with severe heterogeneous emphysema treated with a supportive exhalation valve system had a sustained clinically significant benefit in health-related quality of life at 24 months in the EMPROVE trial. Read more

Pirfenidone may slow lung function decline in patients with rheumatoid arthritis-ILD

In the Phase 2 TRAIL1 trial, treatment with pirfenidone slowed the rate of lung function decline in patients with interstitial lung disease associated with rheumatoid arthritis and demonstrated a safety profile similar to that observed in further drug trials. Read more

Exposure to second-hand airline smoke is linked to worsening respiratory health decades later

Exposure to second-hand tobacco smoke in airlines was strongly associated with poorer respiratory health nearly 3 decades after exposure, researchers reported in Chest. Read more

Tezepelumab reduces mucus obstruction in patients with moderate to severe uncontrolled asthma

Tezepelumab treatment reduced mucus scores, which were correlated with improved lung function, in patients with moderate to severe uncontrolled asthma, researchers reported at the ERS International Congress. Read more

Digital measurement of asthma medication adherence, useful lung function to guide management

Evidence-based care informed by digital data collection has reduced the burden of treatment in patients with severe, uncontrolled asthma, researchers reported at the ERS International Congress. Read more

Inhalation therapy containing manuka honey, amikacin shows promise for respiratory infections

The combination of manuka honey and the antibiotic amikacin in a laboratory nebulizer formulation was effective in inhibiting Mycobacterium abscess and drug-resistant clinical isolates from patients with cystic fibrosis or bronchiectasis. Read more

Global COPD prevalence, deaths and disability-adjusted life years have declined in recent years

Global COPD prevalence, deaths and rates of disability-adjusted life years were lower in 2019 than in 1990, researchers reported in The BMJ. Read more

[ad_2]
Source link

Comments are closed.